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There have been a number of significant devel-
opments in the management of HBV in recent
years, particularly new therapeutic agents that
can be used by both the HIV co-infected and the
HBV mono-infected patient.  IDCR Co-Editor,
David Wohl, MD, interviewed Chloe Thio, MD to
get her perspective on the state of the art of the
management of HBV.  Dr. Thio is an infectious
diseases physician at Johns Hopkins in
Baltimore specializing in the management of
patients with HIV and viral hepatitis co-infection.
She conducts clinical investigations of HBV
therapy and recently published an article in
Clinical Infectious Diseases titled, "Treatment of
Chronic Hepatitis B Infection in HIV-Infected
Persons: Thinking Outside the Black Box." 
Dr. David Wohl (DW):  The prevalence of hepati-
tis B virus (HBV) in prisons and jails in the US is
several fold higher than the general population,
and in many correctional facilities HBV screen-
ing is routinely conducted in inmates who are
HIV-infected, therefore, I want to start by asking
you about the management of HBV in the HIV-
infected patient.  What is your approach to man-
aging HBV in HIV+ inmates who have active
HBV but also have a high CD4 cell count and no
indication for HIV therapy? 
Dr. Chloe Thio (CT):  Before I would even con-
sider HBV therapy in a newly diagnosed patient
with active HBV infection, I would monitor them
for six months to a year just to be sure this is a
chronic infection and not acute HBV.
Specifically, I would look to see if hepatitis B sur-
face antigen (HBsAg) was lost or if the serolog-
ic pattern shifted from hepatitis B e antigen
(HBeAg) positive to negative.  This would help
me determine if this was a person in the midst
of a recent infection and possibly clearing their
virus.  Importantly, even if this is chronic HBV
infection, a small proportion of people will clear
the virus on their own - approximately 0.5% per
year (1).  So, I would monitor closely for a time,
as I'd want to be sure I know the patient before
starting therapy, especially since HBV therapy is
not as effective as we would like.  However, if
the patient has evidence of end-stage liver dis-
ease I would consider therapy sooner.
DW: What if in this case the HBsAg is found to 
persist during the first year?  What would you do
then?
CT:    First, I would check several serological
tests including HBeAg, anti-HBe, and a HBV
DNA level.  I check the HBeAg status to know if
the patient has HBeAg positive or negative
chronic hepatitis B and to follow the HBeAg sta-
tus with therapy. There are some people with
positive HBsAg and normal liver transaminase
levels who have undetectable or low HBV DNA
If you have any problems with this fax transmission please call 800.748.4336 or e-mail us at IDCR@corrections.net
ABOUT IDCR
IDCR, a forum for 
correctional problem solving, targets
correctional physicians, nurses, 
administrators, outreach workers, and
case managers. Published monthly
and distributed by email and fax,
IDCR provides up-to-the moment
information on HIV/AIDS, 
hepatitis, and other infectious 
diseases, as well as efficient ways 
to administer treatment in the 
correctional environment. Continuing
Medical Education credits are 
provided by The Medical Education
Collaborative (MEC). This activity is
jointly sponsored by IDCR and The
Medical Education Collaborative
(MEC). IDCR is distributed to all mem-
bers of the Society of  Correctional
Physicians (SCP) within the SCP pub-
lication, CorrDocs (www.corrdocs.org).
EXECUTIVE EDITOR
Anne S. De Groot, MD
Director, TB/HIV Research Lab,
Brown Medical School
CHIEF EDITOR
David A. Wohl, MD
Associate Professor of Medicine
University of North Carolina
AIDS Clinical Research Unit
DEPUTY EDITORS
Joseph Bick, MD
Chief Medical Officer,
California Medical Facility, California
Department of Corrections
Renee Ridzon, MD
Consultant
SUPPORTERS
IDCR is grateful for 
the support of the following 
companies through unrestricted 
educational grants:
Major Support: Abbott Laboratories
and Roche Pharmaceuticals. 
Sustaining: Pfizer Inc., Gilead
Sciences, Inc., GlaxoSmithKline, Merck
& Co., Schering-Plough,
and Boehringer Ingelheim
MANAGING HEPATITIS B VIRUS INFECTION: AN INTERVIEW WITH
CHLOE THIO, MD - ASSOCIATE PROFESSOR OF MEDICINE, JOHNS
HOPKINS MEDICAL SCHOOL
WHAT’S INSIDE
Editor’s Letter pg 2
Spotlight pg 5
HBV 101 pg 7
Save The Dates pg 8
In The News pg 8
IDCR-O-GRAM  pg 9
Self-Assessment Test pg 10 
August  2006  Vol. 10, Issue 8
FORMERLY HEPP Report
Continued on page 3
J O I N T LY S P O N S O R E D  B Y T H E  M E D I C A L E D U C AT I O N  C O L L A B O R AT I V E ,  I N C .
Hepatitis B Virus Source: Barth K, Frese M. Freiburg University
2Subscribe to IDCR
Fax to 401-272-7562 for any of the following: (please print clearly or type)
____  Yes, I would like to add/update/correct (circle one) my contact information for my complimentary 
subscription of IDCR fax/email newsletter.
____  Yes, I would like to sign up the following colleague to receive a complimentary subscription of 
IDCR fax/email newsletter.
____  Yes, I would like my IDCR to be delivered in the future as an attached PDF file in an 
email (rather than have a fax).
NAME: FACILITY:
CHECK ONE:
ADDRESS: CITY: STATE: ZIP:
FAX: PHONE: 
EMAIL:
Physician Physician Assistant Nurse/Nurse Practitioner Nurse Administrator
Pharmacist          Medical Director/Administrator HIV Case Worker/Counselor        Other
Faculty Disclosure
*Disclosures are listed at the beginning of the articles.
The employees of The Medical Education Collaborative
have no financial relationships to disclose. 
In accordance with the Accreditation Council for Continuing
Medical Education Standards for Commercial Support, the
faculty for this activity have been asked to complete Conflict
of Interest Disclosure forms. Disclosures are listed at the
end of articles.
Associate Editors
Rick Altice, MD
Yale University AIDS Program
David Paar, MD
Associate Professor of Medicine,
University of Texas, Medical Branch
Dean Rieger, MD
Officer/Corporate Medical Director,
Correct Care Solutions
Karl Brown, MD, FACP
Infectious Disease Supervisor
PHS-Rikers Island
Ralf Jürgens
Consultant
Joseph Paris, PhD, MD, FSCP, CCHP
Former Medical Director,
Georgia Dept. of Corrections
Lester Wright, MD, MPH
Chief Medical Officer,
New York State Dept. of Correctional Services
William Cassidy, MD
Associate Professor of Medicine,
Louisiana State University Health Sciences
Center
Bethany Weaver, DO, MPH
Acting Instructor, Univ. of Washington,
Center for AIDS and STD Research
David Thomas, MD, JD
Professor and Chairman,
Division of Correctional Medicine
NSU-COM
Editorial Board
Neil Fisher, MD
Medical Director, Chief Health Officer, 
Martin Correctional Institute
Lynn Taylor, MD
Assistant Professor of Medicine, Brown University
School of Medicine, The Miriam Hospital
Michael Poshkus, MD
Medical Program Director, Rhode Island
Department of Corrections
Louis Tripoli, MD, FACFE
Vice President of Medical Affairs, CMS
Correctional Medical Services
Josiah Rich, MD
Associate Professor of Medicine and 
Community Health
Brown University School of Medicine
Steven F. Scheibel, MD
Regional Medical Director 
Prison Health Services, Inc
Mary Sylla
Director of Policy and Advocacy, 
Center for Health Justice
Barry Zack, MPH
Executive Director, Centerforce
Eric Avery, MD
Jim Montalto
The Corrections Connection
Layout
Jose Colon
The Corrections Connection
Distribution
Screened Images Multimedia
Managing Editor
Elizabeth Closson
IDCR
Dear Corrections Colleagues, 
Viral hepatitis is endemic in correctional populations.  In some systems, over 40% of inmates are infect-
ed with hepatitis C virus (HCV) and outbreaks of hepatitis B virus (HBV) have been reported in correc-
tional settings.  Both viruses can co-infect HIV-positive individuals, complicating HIV management.
Recent data describe increasing rates of mortality due to viral hepatitis among HIV-infected persons and
liver disease is becoming a leading cause of death among patients with HIV.  Given the heavy burden of
hepatitis in prisons and jails, correctional clinicians must become familiar with the detection, prevention
and management of both HCV and HBV.  
In this issue of IDCR, Dr. Chloe Thio, a nationally recognized expert on HBV therapeutics, provides her
perspective on the latest developments in HBV treatment and offers practical advice regarding common-
ly encountered dilemmas in HBV treatment.  IDCR Board Member Dr. Bethany Weaver contributes a case
study on HCV, highlighting the major issues related to counseling, staging and treatment of this all too
prevalent infection.  These instructive articles are supplemented by a list of resources readers can access
to obtain further information.
While this issue was going to press, two major events occurred.  The first was the International AIDS
Society Conference (also called the World AIDS Conference).  There were several major HIV therapeutic
developments presented at the conference and special sessions focusing on prisoners, including a ses-
sion chaired by IDCR Executive Editor Dr. Annie De Groot.  Special coverage of the conference will be
included in the September issue.  In addition, the Institute of Medicine of the National Academies of
Science issued their anticipated report on ethical considerations regarding research involving prisoners.
This important report will also be covered in-depth in the next issue of IDCR.  
Lastly, IDCR and the American Academy of HIV Medicine (AAHIVM) are teaming up to help make the
resources of the AAHIVM accessible to correctional clinicians and are hoping to work together on future
continuing education projects. Visit the AAHIVM website at www.aahivm.org to learn more about the acad-
emy.   
We look forward to reading your responses to what you read in IDCR.  Email me at wohl@med.unc.edu
or Annie De Groot at Annied@brown.edu.   Letters to the editor can be found on the IDCR website.
Sincerely, 
David Alain Wohl, MD
Associate Professor of Medicine
Division of Infectious Diseases
AIDS Clinical Trials Unit
The University of North Carolina - Chapel Hill
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levels (i.e. less than 104) and those people
I would not treat (2).  For those with higher
HBV DNA levels I need to decide whether
their HBV needs to be treated.  In such
cases I would consider getting a liver biop-
sy.  The liver biopsy can be helpful in deter-
mining the need for HBV treatment - espe-
cially in a patient with low HBV DNA levels
(3).  So, for instance, in the case of a
patient with a CD4 cell count of 450/mm3
who has a HBV DNA of 105 I would consid-
er a liver biopsy to determine if treatment is
needed now or can be deferred until HIV
therapy is initiated later on.  If the biopsy
does not show significant liver disease, I
might wait and do nothing except follow
them every six months checking their ALT
and their HBV DNA levels and look for
development of liver problems such as can-
cer.  Such patients will in the next few years
probably need HIV therapy and at that time
I can use drugs that have activity against
both HIV and HBV. 
DW: You are saying that liver biopsies
can help the provider decide if HBV thera-
py is indicated but in many correctional
facilities liver biopsy is difficult to obtain.
How essential is the liver biopsy?
CT: The problem is that you cannot
really rely on HBV DNA levels by them-
selves to tell you who needs HBV treat-
ment.  Therefore, the biopsy can be partic-
ularly helpful in determining whom not to
treat.  Certainly, if someone has an HBV
DNA level of 109 and an ALT of 100, that
person needs treatment and you really do
not need the liver biopsy.  But, if someone
has an HBV viral load that is 105 and an
ALT of 40 it is really hard to know how
much liver damage is present, and a biop-
sy that shows minimal damage may dis-
suade you from treatment while the pres-
ence of more significant disease would
support therapy.  That said, outside correc-
tions we often do get liver biopsies even in
patients with clear cut indications for HBV
therapy to have some idea as to what stage
of the disease they have.  But, without the
luxury of the biopsy if there is a patient who
by HBV DNA and transaminase levels plus
clinical presentation you think needs HBV
treatment, a biopsy is not essential.  In
cases where you are inclined not to treat,
the biopsy becomes more imperative since
you do not want to defer therapy of a
patient with end-stage liver disease just
because they have low levels of HBV DNA
- which can happen.
DW: It sounds like persistent HBsAg
positivity and a HBVDNA level at least 105
copies/ml qualify a patient for therapy.
What about ALT?
CT: ALT is something that we do look
at.  The main reason is that studies have
shown that for people with active HBV and
normal ALT the response to treatment is
very low.  So, we tend not to treat them
unless they have evidence of liver disease.
This relatively low treatment response is
likely because you need an immune
response to the virus in addition to antivi-
rals and those with elevated ALT have
more of an immune response to HBV.
DW: Any other criteria for treatment for
HBV?
CT: For those from Asian countries
but also for people from here, a family his-
tory of liver cancer is important and would
tip me toward treating earlier as HBV is
oncogenic and with that history I am more
aggressive in trying to treat.   Otherwise,
that is it.
DW: For the patient we have been dis-
cussing who has HBV-HIV co-infection and
high CD4+ cell counts and who does qual-
ify for HBV therapy by persistent surface
antigen positivity, HBV DNA levels and ele-
vated ALT, what treatment would you rec-
ommend?  Let's assume he does not want
to or cannot have a liver biopsy. 
CT: Foremost, no patient in this coun-
try should be treated with lamivudine
(Epivir, Epvir-HBV, 3TC) alone as the
active HBV agent - HIV+ or HIV-.
Resistance develops relatively quickly and
can hamstring future therapy.  In this case,
it is unlikely anyone would try to treat this
patient with lamivudine mono-therapy but,
were he to need HIV treatment he could
mistakenly be placed on an antiretroviral
regimen in which lamivudine is the only
active HBV drug.  In the situation of a
patient who does not require HIV treatment
I might consider pegylated interferon-alpha
(Pegasys, Peg-Intron) because it does not
have any effects on developing HIV drug
resistance (4).  Here an HBV genotype
might be helpful as recent studies suggest
that genotype A - the most common in the
US - and genotype D, respond best to this
agent.  So, if he were genotype A that
would push me to pegylated interferon.  If
pegylated interferon cannot be adminis-
tered you would need to use drugs that will
not be active against HIV so as to not risk
HIV drug resistance.  So, in a patient with-
out prior HIV therapy and therefore unlikely
to have lamivudine resistance my first
choice would be entecavir (Baraculude). It
is more potent than the alternative, adefovir
(Hepsesera) (3, 4). In addition, to date,
there is less resistance with entecavir than
with adefovir - but this can be because
entecavir has not been studied as much as
adefovir.  But, entecavir is more potent so I
think we will see less resistance over the
long term.
DW: We learned the hard way in HIV,
and more recently hepatitis C virus (HCV),
infection that mono-therapy is not as effec-
tive as combination therapy.  Should we be
treating HBV with more than one agent?
CT: In the long term we may find that
there might be a combination that is more
potent than mono-therapy.  As I said
before, I would not use lamivudine alone as
resistance develops rapidly.  Now, with
entecavir I feel fairly comfortable using this
agent alone since there is practically 0%
risk of resistance in the first year of treat-
ment.  You can monitor the patient's HBV
DNA levels during that year and if it falls to
undetectable then the risk of resistance is
even closer to zero and you may be able to
get away with mono-therapy.  However, if
the HBV level during the first year does not
become undetectable, you might become
concerned that this patient is at increased
risk for resistance and consider adding a
second drug.
DW: So, you might add adefovir?
CT: Right, I might but there are no
data to support this.  As more data emerge
my algorithm might change.  I think dual
therapy will have its role but unlike HCV
and HIV it may not be a 'one size fits all'
solution.
DW: And, how long are we talking
about as far as HBV therapy?
CT: With pegylated interferon treat-
ment is for a year if you are HBeAg posi-
tive.  If the patient is HBeAg negative then
we really do not know how long to give
pegylated interferon.  There is a study that
showed 24 months of standard interferon
alfa 2b is better than less than 24 months
(5).  We do not know if this is also the case
for pegylated interferon alpha.  In general, I
am less excited about using pegylated
interferon in someone who is HBeAg nega-
tive as it tends to be longer term therapy
and the response rates are not that great
compared to those who are Hepatitis B e
antigen positive - especially if they are
genotype A. 
For the nucleoside and nucleotide ana-
logues the duration of therapy differs based
on the HBeAg status. In persons with
HBeAg-negative chronic Hepatitis B, indef-
inite therapy is needed since rebound
invariably occurs. In HBeAg-positive dis-
ease, therapy can be stopped a minimum
of six months after anti-HBe seroconver-
sion but patients need to be monitored for
relapse since it does occur. 
DW: How do you monitor for treatment
success once starting HBV therapy?
CT: For the first year at least I like to
monitor every three months by getting a
HBV DNA level and liver enzymes.  In a
correctional setting if that is impractical, I
think every six months is also fine but you
get a better sense of how the patient is
doing with more frequent monitoring.   If the
HBV DNA is not undetectable after a year
of therapy, consultation with a hepatitis
specialist is in order.
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DW: Our goal is undetectable?  Not
just a substantial reduction in viremia?
CT: Undetectable is my goal.  We
actually do not know what level of virus you 
need to obtain to reduce the risk of resis-
tance mutations or stop the progression of
liver disease but for now we should shoot
for undetectable.
DW: Let's talk for a moment about the
HIV-infected patient who has a history of
lamivudine exposure.  How is the manage-
ment of this patient different?
CT: With prior exposure to lamivudine,
you have to suspect there is lamivudine
resistance.  There are resistance tests for
HBV that can be performed by central lab-
oratories but if there is a history of pro-
longed lamivudine treatment that may be all
you need.   If you are not ready to treat their
HIV, then the options you have are adefovir
or entecavir.  I wouldn't use pegylated inter-
feron since there is a recent study showing
that HIV-uninfected people with lamivudine
resistance respond less well to this agent
(6).  Or, you can consider the combination
of adefovir and entecavir.  Adefovir has
been shown to be effective in lamivudine-
resistant HBV.  Entecavir is also effective
but the lamivudine resistance mutations are
part of those that are required to lead to
entecavir resistance.  In the first year of
treatment, about 7% of persons with
lamivudine resistance develop entecavir
resistance (4).
DW: If you were going to start HIV ther-
apy what would you choose?
CT: I use tenofovir (Viread) along with
lamivudine or emtricitabine (Emtriva, FTC)
- Truvada (Tenofovir+FTC fixed dose com-
bination) is easy to use.  Obviously, in a
patient with lamivudine-resistant HBV,
emtricitiabine would not be an active drug
but we have learned from the HBV mono-
infected that in lamivudine-resistant
patients treated with adefovir, co-adminis-
tration of lamivudine delayed adefovir resis-
tance.  So, I would use lamivudine or
emtricitabine here even though there are
no data looking at this phenomenon with
tenofovir - but I am extrapolating from the
adefovir experience.
DW: What about HBV treatment for the
HIV-uninfected patient?
CT: What therapy I use depends on
whether someone is HBeAg positive or not.
If someone is HBeAg positive there is much
more resistance data for entecavir than for
tenofovir so if I am only going to use one, I
would choose entecavir over tenofovir.
Their potency is probably equivalent and
my guess is that there will be little tenofovir
resistance in the first year but it has not yet
been studied in mono-infected patients so I
tend not to use tenfovir alone and instead
use Truvada - even in the mono-infected
patients.  Being HBeAg negative changes
things and these are almost two different
diseases.  People with negative HBeAg
require long-term therapy.  Those who are
HbeAg positive you are able to monitor for
conversion to anti-HBe positive and then,
when that happens, stop therapy six
months after seroconversion occurs.  In
HbeAg negative patients if you stop thera-
py they almost always rebound.  So, in the
HbeAg negative situation I virtually never
use mono-therapy since I know they are
going to be on the drug a long time. 
DW: I am going to shift gears and ask
you to clarify an issue that is getting
increasingly confusing.  How should we
screen people with HIV-infection for HBV
infection?  A recent study by Raj Gandhi
and colleagues from Harvard Medical
School suggests that isolated Hepatitis B
core antibody (anti-Hbc) may be falsely
positive in a large proportion of HIV-infect-
ed people (7).  In this particular study
patients with anti-Hbc detected on HBV
serologic testing but no other serologic evi-
dence of HBV infection had a very muted
response to HBV vaccination suggesting
the absence of an anamnestic response
that would be expected if there was prior
HBV exposure.
CT: This is an issue where we really
do not know the answer.  In terms of
screening to vaccinate for HBV I would only
order the HbsAg and anti-Hbs and not the
anti-Hbc.  That way you are never stuck
with the situation of the isolated anti-Hbc.  If
both the surface antigen and antibody were
negative, I would vaccinate.  This is one
approach.  In cases where there is isolated
core antibody detected, I would obtain an
HBV DNA.  If that reveals no virus detected
I would check it again in six months along
with their serologies.  If the result were the
same I would vaccinate them for HBV.
DW: Do you ever check for HbeAg or
anti-Hbe?
CT: The paper by Raj Gandhi found
that people who had anti-Hbe present were
less likely to have their anti-Hbc be a false
positive result (7).  If you are worried about
the core antibody being a false positive you
could check the anti-Hbe but it would not
change my management, as I would still
vaccinate them to try to elicit surface anti-
body.
DW: While we are on the topic of HBV
vaccine, what dose do you use?  The data
on response to HBV vaccination among
HIV-infected patients indicates a generally
low response rate.  Dialysis patients often
receive a higher dose (40 ug) of the vac-
cine compared to the standard dose (20 ug)
to overcome a similar suboptimal response
rate.
CT: I initially start out with the stan-
dard dose vaccine and then if they do not
respond, I administer the renal dose of the
vaccine.
DW: Then you must be checking for
hepatitis B surface antibody (anti-HBs)
response in everyone you vaccinate?
CT: Correct.  As you said, vaccine
rates are low and you want to know if they
respond appropriately.  If they don't, despite
a higher dose vaccine, then you want to
know just for the purpose of counseling the
patient. 
DW: Thanks for taking time out to do
this. 
CT: Thank you.
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Case 1: A 36 year-old man presents to
your clinic five days after his arrest for dri-
ving with a suspended license. He reports
that he has a 10-year history of hepatitis C
virus (HCV) infection and was diagnosed
with AIDS after developing Pneumocystis
jiroveci pneumonia (formerly known as
Pneumocystis carinii pneumonia). He has a
prior history of injection drug and alcohol
use but has not used alcohol or injected
drugs for five years. He has a history of
depression without psychosis but one pre-
vious suicide attempt seven years ago.
Four years ago he was prescribed a selec-
tive serotonin reuptake inhibitor (SSRI) for
depression and he continues on this anti-
depressant without symptoms of major
depression. 
At the time of his arrest he was in HIV care
at a local community clinic.  He is receiving
didanosine (Videx-EC), lamivudine, and
efavirenz (Sustiva) and his most recent lab-
oratories obtained 2 months ago revealed a
CD4 cell count of 250/mm3 and unde-
tectable HIV-1 viral load. He has never
received treatment for HCV. You ask him
what the status of his liver disease is (i.e.
liver biopsy results, HCV genotype, HCV
quantitative viral load) and he tells you he
has "no idea" and that he has never had a
biopsy.
Question: Assuming he will only be at the
jail for a short time (i.e. 3 months or less)
thereby making HCV treatment at your jail
facility an unrealistic option, what informa-
tion could you offer this inmate so that his
chances of survival are improved after
release?
Discussion: Given the time constraint,
counseling needs to focus on providing the
patient with the information that will enable
him to make informed choices regarding his
HCV care once he returns to the communi-
ty. That HCV and subsequent cirrhosis is
now a leading cause of death among those
with HIV infection is important for this
inmate to appreciate. The inmate should be
informed that there are many potential ben-
efits of HCV treatment with pegylated inter-
feron (peg-IFN) plus ribavirin.  These
include the possibility of achieving HCV
eradication (i.e. sustained virologic
response, SVR).  The odds of such eradi-
cation depend on several factors including
the genotype of the infecting virus and the
degree of liver damage.  If he has genotype
1 HCV - the most common in the US - he
would have an approximately 15-40%
chance of HCV eradication as someone co-
infected with HIV.  Large trials demonstrate
that additional factors associated with SVR
include lower baseline HCV RNA level (less
than 800,000 IU/ml), absence of cirrhosis,
lower body weight (< 75 kg), younger age,
tolerance of a higher ribavirin dose (at least
10.6 mg/kg per day in those with genotype
1), and adherence to treatment.  Beyond
cure, there are other potential benefits of
HCV therapy including reduced risk of liver
failure and complications related to HCV,
such as cryoglobulinemia and hepatocellu-
lar carcinoma, and possible reversal of
early cirrhosis.  HCV treatment may also
retard or reverse disease progression for
individuals with hepatic fibrosis who are at
greatest immediate risk for end stage liver
disease and death.  
However, this inmate should also be cau-
tioned regarding the demands and risks of
HCV therapy.  The patient should under-
stand that treatment does require injected
and orally administered medications and
can lead to an array of predictable side
effects such as worsening depression and
fatigue.  Most of these adverse effects are
reversible with discontinuation of HCV
pharmacotherapy, although a minority may
be permanent.
Many patients and providers remain
unaware that approximately 15% of individ-
uals with HCV antibodies do not have
detectable levels of HCV in the blood and
have probably cleared the virus on their
own. Thus all patients who are seropositive
for HCV should have a plasma HCV RNA
level checked.  
Importantly, all persons with HCV infection
and a history of substance and alcohol
dependency must be informed that many
providers will not offer HCV treatment
unless the patient has been "clean" from
alcohol and/or illicit drugs for six months or
more, despite a paucity of supporting data.
This incarceration is a good opportunity to
discuss prevention of HCV transmission
including shared needles, sexual behaviors
involving blood such as fisting, and others
(perinatal, occupational, hemodialysis,
household exposure to contaminated
blood).
Referral to a clinic or center where HCV
therapy is available should be made prior to
release.
Case 2: Now assume the same inmate is
seen by you in prison after being sentenced
to three years. 
Questions: If HCV treatment is an option
at your facility, what would be the most
appropriate work-up for this patient before
beginning a discussion of treatment with
him and why?  If you establish that he is a
good candidate for HCV treatment, what
other tests might you order before treat-
ment?  What toxicities associated with peg-
IFN and ribavirin should you be aware of
and counsel your patient about? Would you
continue didanosine, lamivudine, and
efavirenz during the HCV treatment?
Discussion: Conduct a thorough physical
examination looking for signs of decompen-
sated liver disease (e.g. ascites) and evi-
dence of an untreated opportunistic infec-
tion.  Decompensated liver disease and/or
untreated opportunistic infection represent
contraindications to HCV treatment. HCV
treatment could be revisited as a potential
option only if the opportunistic infection is
treated and the patient stabilizes on treat-
ment; once decompensation occurs, it is
5
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Consider discontinuation of therapy in gento-
type 1-4 patients who do not achieve unde-
tectable HCV RNA levels or a 2-log (100-fold)
drop from baseline in the 12th week. Consider
risks/benefits and base decision on case-by-
case basis. 
Treatment should be discontinued in genotype
1-4  patients who have detectable viremia at
week 24 despite a 2-log reduction in viral load
in the 12th week. 
Table 1: Rules for Discontinuation of Treatment with 
Peginterferon + Ribavirin in HIV/HCV Co-infected Patients
Table 2: Peginterferon and Ribavirin Dosing in HIV/HCV 
Co-infected Patients
The 12-week rule
The 12-week rule
Peginterferon alfa-2a
Peginterferon alfa-2b
Ribavirin-2 (divided oral
doses daily)
For all genotypes 180 mcg SQ once weekly
For all genotypes 1.5 mcg/kg SQ once
weekly     
All genotypes: weight <75 kg 1,000 mg
All genotypes: weight >75 kg 1,200 mg
Duration of therapy
Genotype 1 or 4:
Genotype 2 or 3:
48 wks
48 wks 
Modified from: Cotler S. Hepatitis C: transmission to treatment. Infectious Disease Special Edition. 2004;7:15-22 and Strader DB et al. Diagnosis, manage-
ment, and treatment of hepatitis C (AASLD Practice Guideline). Hepatology. 2004;39(4):1147-71. 
6too late for peg-IFN - refer for liver trans-
plant. In individuals with decompensated 
liver disease/cirrhosis, an ultrasound and
alpha-fetoprotein level every six months to
screen for hepatocellular carcinoma should
be performed.  You might consider perform-
ing a liver biopsy to rule out other cor-
rectable causes contributing to the liver fail-
ure (e.g. hepatic steatosis secondary to
antiretroviral therapy, iron overload) if non-
invasive evaluations (e.g. serum alpha 1
antitrypsin, iron studies) are inconclusive,
or to determine the degree of fibrosis.
Experts currently recommend treating
those with advanced HIV/AIDS (absolute
CD4 cell count less than 200/mm3) with
antiretroviral medications first, in an effort to
achieve a CD4 cell count that is above
200/mm3 prior to HCV treatment, though
some patients may not achieve this goal
despite having a fully suppressed HIV viral
load and would still be candidates for HCV
treatment. 
As far as laboratory studies, as described
above, HCV genotype and RNA quantita-
tive viral load should be ordered as should
a complete metabolic panel (chemistries,
transaminases, total bilirubin, albumin) ,a
complete blood count with platelets, and a
CD4 cell count.  If the HCV RNA viral load
is undetectable and remains undetectable
at subsequent visits, no HCV treatment is
necessary since there is no evidence of
chronic HCV infection. In addition, knowing
the HCV genotype allows you to give the
patient a projected prognosis with treat-
ment, as not all genotypes respond the
same to treatment (see figure 1 -
"Response to pegylated interferon alfa-
2a/ribavirin in HCV patients by genotype"). 
A subsequent evaluation for HIV/HCV co-
infected patients who have evidence of
viremia and no evidence of decompensated
liver disease should include a prothrombin
time-international ratio, ferritin, alpha 1
antitrypsin level, and ceruloplasmin to
screen for other causes of hepatic fibrosis,
hepatitis A and B serologies to screen for
those eligible for immunization, a pregnan-
cy test for women, a rapid plasmin reagent
(RPR) to screen for syphilis, TSH,  diabetes
and depression screen, antinuclear anti-
body to screen for autoimmune hepatitis, a
retinal exam, especially for those with pre-
existing retinopathies of other causes (e.g.
diabetes mellitus, cytomegalovirus, hyper-
tension), and a liver biopsy, particularly
those with HCV genotype 1.  A baseline eye
exam is recommended because the use of
interferon has been associated with retinal
vascular occlusion and hemorrhages, cot-
ton-wool spots, and optic neuropathy. 
A creatinine clearance less than 50 mL/min
contraindicates the use of ribavirin, which is
a component of the standard HCV treat-
ment regimen. However, peg-IFN may still
be used alone in patients with significant
renal impairment.  Other contraindications
to HCV treatment with ribavirin and peg-IFN
include autoimmune disease, coronary
artery disease, pancreatitis, pregnancy, and
current major depression - especially if
untreated/unstable from a mental health
perspective. Ongoing injecting drug or alco-
hol use is not necessarily a contraindication
to HCV treatment and should be evaluated
on a case-by-case basis. HCV treatment
may be deferred in those with only mild his-
tologic changes, in which case a liver biop-
sy could be repeated in 2-3 years to assess
for disease progression. If abnormalities
such as renal impairment, anemia, thyroid
disease, depression, diabetes, retinopathy,
iron deficiency or overload are detected,
they should be addressed and controlled
before considering HCV treatment. 
When co-administered with peg-IFN and
ribavirin, the use of several antiretroviral
agents have been associated with higher
risk of liver toxicity, such as hepatic steato-
sis and failure.  For example, didanosine is
absolutely contraindicated with HCV thera-
py given the increased risk of hepatic
steatosis and lactic acidosis. In this case,
didanosine must be discontinued if the
patient is to receive HCV therapy.
Alternatives include tenofovir and abacavir.
Anemia secondary to the co-administration
of zidovudine (Retrovir)  and ribavirin can
occur and be particularly severe requiring
the use of other costly measures, such as
erythropoietin and reduction of the dose of
ribavirin - decreasing the likelihood of
achieving SVR.  Therefore, appropriate
alternatives to zidovudine should be sought
during HCV therapy.  There is a potential
inhibitory effect of ribavirin on zidovudine,
and stavudine (Zerit) observed in vitro, but
this has not been reported as a clinically
significant affect in vivo.  Neuropathy, a
common side effect among those taking
stavudine, didanosine, or zidovudine, may
be exacerbated in patients also receiving
peg-IFN.  
Please refer to Tables 1 and 2 for rules for
discontinuation and dosing of peg-IFN and
ribavirin in HIV/HCV co-infected patients. 
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Drug Dose FDA approved to treat CHB/HIV coinfection 
Active
Against HIV Comments
IFN-alpha
Pegylated IFN-alpha
Emtricitabine (FTC)
Lamivudine (3TC)
Adefovir
Tenofovir (TDF)
Entecavir
5 MU daily or
10 MU 3X/wk
180 ug/wk 
by injection
for 6-12 mo.
300 mg daily in 
HIV-infected 
patients minimum
treatment duration 
of 12 mo. 
200 mg daily,
optimal duration
unknown. 
10 mg daily,
optimal duration
unknown
300 mg daily, 
optimal duration 
unknown
0.5 mg daily
in lamivudine-
naïve patients.
1.0 mg in 
lamivudine-experi-
enced; optimal
duration unknown
No
Few studies show suc-
cess. Perhaps better with
high ALT levels and CD4
lymphocyte 
count >350 cell/mm3.
Better than lamivudine
in one study of HBV 
HBeAg-negative
patients w/ CHB. **
Resistance rate of 
20-25%/yr among HBV 
isolates from HIV-infected
patients. Do not include
in HAARRT as the only
HBV active agent.
Similar in structure 
to lamivudine, so
expected have same
rates of resistance.
Concerns about HIV
resistance emerging to
tenofovir may limit use.
Recommended use as
part of a HIV-replication-
suppression regime. 
No resistance during first
48 wks in treatment
naïve patients.
Resistance at 48 wks in
HBV isolates from 7% of
patients withlamivudine-
resistant HBV.
Modified from: Thio CL, Sulkowski MS, Thomas D. Treatment of Chronic Hepatitis B in HIV-Infected Persons: Thinking Outside of the Black Box. Clin Infect Dis. 2005;41:1035-40. 
* Anti-HIV activity was noted in an HIV-hepatitis C virus coinfection trial - Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.
Peginterferon alfa-2a pluc ribaviron for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-50. 
** Marcellin P, Lau GKK, Bonino F, et al. Peg-interferon alfa-2a (40KDa) (Pegasys) monotherapy is more effective than lamivudine
monotherapy in the treatment of HBeAg negative chronic hepatitis B: 72 week results from a phase III, partially double-blind study of
Pegasys alone vs. Pegasys plus lamivudine vs. lamivudine [abstract 95]. In: Program and abstracts of the 39th Meeting of the
European Assoc. of the Study of Liver Disease (Berlin). Geneva, Switzerland: Keyes International, 2004. 
No
No
No
No
No
Yes
No
Yes*
Yes
Yes
No
Yes
No
7th Annual Inside/Out Summit
"Rehabilitation Re-emerges: Working Together
to Help Those Affected by Incarceration"
September 11- 12, 2006
San Francisco, CA
Program and Hotel Info:
Visit: www.centerforce.org/summit
Tiffany Barber, Summit Coordinator
# 415 456 9980 X 135
E-mail: ybarraj@mail.amc.edu
Correctional Medicine Institute's 2006
Intensive Review in Correctional Medicine
September 15-17, 2006
Baltimore, MD
Visit: http://www.cmi2006.org/
2006 United States Conference on AIDS
(USCA)
September 21-25, 2006
Hollywood, FL
Westin Diplomat Hotel 
Visit: http://www.nmac.org/conferences___train-
ings/USCA/
46th Annual Interscience Conference on
Antimicrobial Agents and Chemotherapy
(ICAAC)
September 27-30, 2006 
San Francisco, CA
Visit: http://www.icaac.org/
44th Annual Infectious Diseases Society of
America (IDSA) Conference
October 12-15th, 2006
Toronto, Ontario, Canada
Visit: www.idsociety.org
"Managing Addiction in the HIV-infected
Patient"
Live Satellite Video Conference
Part of Management of HIV/AIDS in the
Correctional & Community Setting
October 18, 2006
Albany Medical College 12:30-2:30 
CME & CNE credits available
Visit: www.amc.edu/HIVConference
E-mail: ybarraj@mail.amc.edu
Infectious Disease in Corrections Report
(IDCR) Symposium
"Intensive review of ID in Correctional Health" 
Pre-conference before the NCCHC Conference
Saturday Afternoon, October 28, 2006
CME credits available
Hyatt Regency Hotel Atlanta, GA
Visit: http://www.ncchc.org/education/nation-
al2006/atlanta.html
National Commission on Correctional Health
Care (NCCHC) Conference
October 28- November 1, 2006 
Hyatt Regency Hotel
Atlanta, GA
Visit: http://www.ncchc.org/education/nation-
al2006/atlanta.html
134th Annual American Public Health
Association (APHA) Meeting and Exposition 
November 4-8, 2006
Boston, MA
Visit: http://www.apha.org/meetings/
6th National Harm Reduction Conference
November 8-12, 2006 
Oakland, CA
Visit: http://www.harmreduction.org/6national/
University of Texas Medical Branch (UTMB)
HIV Mini-Fellowship
November 13-15, 2006
Moody Gardens Hotel and Convention Center
Galveston, TX 
$50.00 Registration Fee
CME and CNE credits available
Contact: Victoria Korschgen 
E-mail: vikorsch@utmb.edu
Phone: (409)772-8799
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Predictors of response to hepatitis A vaccine in
HIV-positive patients
US Public Health Service/Infectious Diseases
Society of America guidelines for the prevention of
opportunistic infections in HIV-infected individuals
recommend that hepatitis A virus (HAV) vaccination
be given to all HIV+ patients, particularly those with
other chronic conditions such as hepatitis C virus
infection.  To determine the predictors of immune
response to the HAV vaccine, researchers in New
Haven, CT retrospectively examined the medical
records of outpatients attending area HIV clinics.  At
these clinics baseline and post-vaccination HAV
antibodies are measured routinely.  Those who are
found to be HAV susceptible are administered two
doses of the HAV vaccine (1440 ELISA units given
IM 6-12 months part).  Of the 503 patients who had
HAV serologic testing performed, 138 were HAV
seronegative at baseline and completed both injec-
tions of the series.  Less than half (48.5%) of these
patients had evidence of a serologic response to
the HAV vaccine series.  In a multivariate analysis
examining response to the HAV vaccine, being
female and having a CD4 count >200 cell/mm3 at
the time of initial vaccination were independent pre-
dictors of adequate response. Hepatitis C virus
(HCV) exposure, antiretroviral therapy use, age and
race were not different between responders and
non-responders. These data suggest that delay of
HAV vaccination until CD4 cell counts increase fol-
lowing HAART initiation may improve immune
responses to HAV vaccine, especially among men. 
Weissman S, Feucht C, Moore BA. Journal of Viral
Hepatitis. 2006;13(2):81-86. 
A comparison of entecavir and lamivudine for
chronic hepatitis B virus infection.
Two large clinical trials pitted entecavir and lamivu-
dine for the treatment of chronic HBV infection in
HIV-uninfected patients.   Chang and colleagues in
Taiwan randomized 715 HBeAg-positive patients
naïve to nucleoside analogues to lamivudine or
entecavir for at least 52 weeks. The primary effica-
cy end point was histologic improvement (a
decrease by at least two points in the Knodell
necroinflammatory score, without worsening of
fibrosis) at week 48. Secondary end points included
a reduction in the serum HBV DNA level, HBeAg
loss and seroconversion, and normalization of the
alanine aminotransferase level.  At 48 weeks, histo-
logic improvement was seen in 72% of the ente-
cavir assigned patients compared to 62% of those
receiving lamivudine (p = 0.009). Further, entecavir
treated patients had deeper declines in HBV viral
load (6.9 vs. 5.4 log10 copies/mL, P<0.001).  There
was no difference in HBeAg seroconversion
between the study arms (~20% in each group).
Entecavir resistance was not detected during the
first year of treatment and tolerability to the two
agents was similar.
Lai and colleagues across the South China Sea in
Hong Kong conducted a similar head-to-head of
entecavir and lamivudine but enrolled HBeAg-neg-
ative patients.  A total of 648 patients were random-
ized and as was seen in the trial of HBeAg-positive
patients, entecavir yielded significantly greater
rates of histologic improvement.  Again, 70% of
those assigned entecavir versus 60% of those
receiving lamivudine had histologic improvement
on liver biopsy (p = 0.01).  HBV DNA levels were
undetectable in 90% of the entecavir group com-
pared to 72% of the lamivudine group (p < 0.001).
Normalization of ALT levels was seen in 78% and
71% of the entecavir and lamivudine patients,
respectively (p = 0.045).  As in the Taiwanese study,
resistance to entecavir was not observed and there
were no differences between arms in safety para-
meters.
In an editorial accompanying these papers, Jay
Hoofnagle, MD of the National Institutes of Health,
adds some temperance to any irrational exuber-
ance concerning these results pointing out that cur-
rent HBV therapies suppress but do not eradicate
HBV infection - unlike successful HCV therapy.
Therefore, there remains debate regarding which
patients should be treated, with which agent(s) and
for how long (see Main Article).  These studies do
demonstrate that entecavir is potent, relatively less
prone to cultivate drug resistance and seemingly
safe (high does of the drug in mice have been found
to cause cancer).  These qualities, Dr. Hoofnagle
writes, make entecavir along with adefovir a rea-
sonable first line therapy choice for HIV-negative
chronic HBV-infected patients.
Chang TT, Gish R, de Man, R et al. A Comparison of
Entecavir and Lamivudine for HbeAg-Positive Chronic
Hepatitis B. N Engl J Med. 2006;354(10):1001-10. 
Lai CL, Shouval D, Lok AS. Entecavir verus lamivudine for
patients with HbeAg-negative chronic hepatits B. N Engl J
Med. 2006;354(10):1011-20
Hoofnagle J.  Hepatitis B--preventable and now treatable.
N Engl J Med. 2006 Mar 9;354(10):1074-76.
FDA updates black box warning on
Aptivus (tipranavir)
On June 30th, 2006 the FDA updated the black box
warning on tipranavir  protease inhibitor that is used
in combination therapy with ritonavir (Norvir) for
HIV-infected patients resistant to other drugs. The
new warning is a result of 14 documented cases of
intracranial hemorrhage in 13 of 6,840 people who
took tipranavir during clinical trials.  Eight of the 13
people died as a result of the hemorrhaging.
According to the company, during an in-vitro exper-
iment, tipranavir was observed to inhibit human
platelet aggregation. Further, studies in rodents
found an increase in coagulation parameters -
increased prothrombin time (PT) and activated par-
tial thromboplastin time (PTT).  Such changes were
not observed in experiments of dogs.  A 'Dear
Doctor' letter sent to providers recommends that
tipranavir/ritonavir should be used with caution in
patients who may be at risk of increased bleeding
from trauma, surgery or other medical conditions, or
who are receiving medications known to increase
the risk of bleeding such as antiplatelet agents or
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anticoagulants.  The warning label has previ-
ously sited liver failure as a possible effect of
the drug. 
http://www.fda.gov/medwatch/safety/2006/Aptivus
-tipranavir_DHCP.pdf
http://www.fda.gov/medwatch/safety/2006/Aptivus
_PI.pdf
FDA Approves New HIV Medications:
Fixed dose tenofovir, emtricitabine and
efavirenz (Atripla)
The US Food and Drug Administration on
July 12th approved a fixed dose once daily
tablet combining efavirenz, emtricitabine
and tenofovir - efavirenz - for the initial treat-
ment of adults with HIV-1 infection. In the
Department of Health and Human Services
Guidelines for the Use of Antiretroviral
agents in HIV-1-Infected Adults and
Adolescents, the components of Atripla are
recommended as one of the first-line regi-
mens for treatment naïve patients. The side
effects of the medication should be no differ-
ent than its individual components. In
patients with chronic hepatitis B virus (HBV)
infection, the disruption of this new treament
may cause greater severity of HBV infection
as tenofovir and emtricitabine are potent
anti-HBV agents. The efficacy and safety of
this new treament  was demonstrated in a 48
week long clinical study and pharmacokinet-
ic studies indicate comparable bioavailability
of the components to that observed when
administered individually. 
The U.S. Food and Drug Administration. FDA
News. Available at: http://www.fda.gov/bbs/top-
ics/NEWS/2006/NEW01408.html
Darunavir (Prezista)
Tibotec's darunavir, also known as TMC-114,
a new protease inhibitor for HIV-infected
patients who have developed resistance to
other ARV therapy received accelerated
FDA approval in June. The drug, co-admin-
istered with ritonavir, was approved based
on the findings of two randomized controlled
studies examining the safety and efficacy of
the darunavir/ritonavir in heavily treatment
experienced patients. As a condition of the
accelerated approval of the drug, Tibotec will
conduct studies to evaluate the clinical ben-
efits of darunavir. It will also perform studies
on the effects of the drug in children and
patients with liver dysfunction.  
The U.S. Food and Drug Administration. FDA
News. Available
http://www.fda.gov/bbs/topics/NEWS/2006/NEW0
1395.html
RESOURCES
Bureau of Justice Prison Statistics Hepatitis
Testing and Treatment
http://www.ojp.usdoj.gov/bjs/abstract/httsp.htm
CDC Patient Information on Viral Hepatitis
http://www.cdc.gov/ncidod/diseases/hepatitis/
CDC Hepatitis C Coordinator Web site Portal
http://www.cdc.gov/ncidod/diseases/hepatitis/reso
urce/coordinators_portal.htm
Federal Bureau of Prisons Hepatitis C Clinical
Practice Guidelines 2005
http://www.bop.gov/news/PDFs/hepatitis.pdf
Diet Recommendations for Hepatitis C Infected
Individuals
http://www.dietitians.ca/resources/HepatitisC_Gui
delines.htm
Hepatitis B Vaccination Coverage Among
Adults --- United States, 2004
MMWR May 12, 2006 / 55(18);509-511
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm
5518a3.htm
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Clinical management of ARV-associated hepatotoxicity in patients with HIV/HCV coinfection
Modified from: Berggren R. Management of patients coinfected with HIV and hepatitis C virus. Infectious Disease Special Edition. 2004;7:26-29. 
* Based on Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretro
viral therapy. AIDS 2001;15:1261-1268.
** Consider acute hepatitis A and B virus infection, other infectious causes of hepatitis, and nucleoside analog reverse transcriptase
inhibitor-related lactic acidosis syndrome due to mitochondrial toxicity.
***Patients that have grade 3 or 4 hepatotoxicity and no symptoms of acute heptatitis who remain on ARV therapy should be moni-
tored closely. 
Increase serum ALT or AST
levels after initiation of 
ARV therapy
Grade 1 or 2 increase 
(defined as <5 X upper limit of base-
line normal value or <3.5 X the base-
line abnormal value)*.
Does patient have symptoms of
acute hepatitis C,  mitochondrial toxi-
city,or a hypersensitivity reaction (eg.
to nevirapine or abacavir)?
Yes
Follow algorithm for grade 3 or 4
increase in serum ALT or AST levels.
No
ALT or AST levels monthly. Continue
ARV therapy. Monitor serum ALT or
AST levels monthly.
Grade 3 or 4 increase (defined as
either >5 X upper limit of baseline
normal value or >3.5 X the baseline
abnormal value).
Exclude alternative causes of acute
hepatitis. ** Consider discontinuation of
ARV therapy.*** If suspicious of mito-
chondrial toxicty or a hypersensitivuty
reaction (eg. to nevirapine or abacavir)
Decrease in serum ALT or AST lev-
els after discontinuation of ARV ther-
apy.
No change or increase in serum ALT
or AST levels after discontinuation of
ARV therapy.
Reinitiate ARV therapy with new
drug regime. Monitor serum ALT or
AST levels closely.
Consider liver biopsy and treatment
of underlying liver disease (eg.HCV
infection).
SELF-ASSESSMENT TEST FOR CONTINUING MEDICAL EDUCATION CREDIT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for continuing
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1. Treatment of hepatitis B virus (HBV) infection is indicated in 
patients with the following EXCEPT:
A. Evidence of chronic HBV infection such as persistent 
positive HBsAg
B. HBV DNA level that is greater than 104 copies/mL
C. Normal ALT level
D. A family history of hepatocellular carcinoma
2.  In patients who meet criteria for HBV therapy and have never
been exposed to lamivudine which of the following are considered
suitable therapies:
A. Lamviudine
B. Entecavir
C. TDF
D. A or B
E. Neither A or B
3.  In the setting of HBV-HIV co-infection treatment of HBV must
take into consideration overlapping drug resistance of antivirals for
each infection.  Which of the following agents have activity against
both HIV and HBV?
A. Tenofovir
B. Lamivudine (3TC)
C. Emtricitibine (FTC)
D. Entecavir
E. A, B and C
4.  Factors associated with response to HCV therapy include
which of the following:
A. HCV genotype (genotype 1 is less responsive) 
B. Lower plasma HCV viral load
C. Lower body weight
D. Tolerance of higher doses of ribavirin
E. All the above
5.  Didanosine should never be co-administered with HCV therapy
True or False?
A. True
B. False
In order to receive credit, participants must score at least a 70% on the post test and submit it along with the credit 
application and evaluation form to the address/fax number indicated.  Statements of credit will be mailed within 6-8 weeks
following the program.
Please print clearly as illegible applications will result in a delay.
Name: _________________________________________________  Profession: __________________________________
License #: ___________________________________  State of License: __________________________________________
Address: ____________________________________________________________________________________________
City: ________________________ State: ________ Zip: ________________________ Telephone: ___________________
Please Check which credit you are requesting  ___ ACCME   or    ___ Non Physicians
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
I certify that I participated in IDCR monograph - August 2006 Issue     
Please fill in the number of actual hours that you attended this activity.
Date of participation: ______________________  
Number of Hours (max. 1.25): ___________________
Signature: _________________________________________________
Please Submit Completed Application to:
Medical Education Collaborative
651 Corporate Circle, Suite 104, Golden CO 80401
Phone: 303-420-3252 FAX: 303-420-3259
For questions regarding the accreditation of this activity, please call
(303)420-3252
Instructions:
• Applications for Credit will be accepted until 
August 31, 2007.
• Late applications will not be accepted.
• Please anticipate 6-8 weeks to recieve your certificate.
Objectives:
The learner will be able to list major criteria for treatment of hepatitis B virus (HBV) infection.
The learner will understand the need to choose HBV therapies that will not cultivate HIV drug resistance in the HBV-HIV co-infected patient.
The learner will be able to cite predictors of response to treatment of hepatitis C virus (HCV) infection.
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COURSE EVALUATION
I. Please evaluate this educational activity by checking the appropriate box:
Activity Evaluation
Faculty
Content
How well did this activity avoid com-
mercial bias and present content that
was fair and balanced?
What is the likelihood you will
change the way you practice based
on what you learned in this activity?
Overall, how would you rate 
this activity?
Excellent Very Good Good Fair Poor
II. Course Objectives 
Were the following overall course objectives met?  At the conclusion of this presentation, are you able to:
• The learner will be able to list major criteria for treatment of hepatitis B virus (HBV) infection. YES NO SOMEWHAT
• The learner will understand the need to choose HBV therapies that will not cultivate HIV drug             YES NO SOMEWHAT
resistance in the HBV-HIV co-infected patient.
• The learner will be able to cite predictors of response to treatment of hepatitis C virus YES NO SOMEWHAT
(HCV) infection.
III. Additional Questions
a. Suggested topics and/or speakers you would like for future activities.
b.  Additional Comments 
